Group 1 - The stock of Brainsway Ltd. (BWAY) is experiencing significant attention due to high implied volatility in the options market, particularly for the Jan 16, 2026 $12.50 Call option [1] - Implied volatility indicates the market's expectation of future movement, suggesting that investors anticipate a significant price change or an upcoming event that could impact the stock [2] - Brainsway currently holds a Zacks Rank 3 (Hold) in the Medical - Products Industry, which is in the bottom 34% of the Zacks Industry Rank, indicating a relatively weak position in the market [3] Group 2 - Over the past 60 days, two analysts have raised their earnings estimates for Brainsway for the current quarter, while one has lowered theirs, resulting in a net increase in the Zacks Consensus Estimate from three cents to four cents per share [3] - The high implied volatility may present a trading opportunity, as options traders often seek to sell premium on options with elevated implied volatility, aiming to benefit from the decay of options value [4]

Shares of Brainsway Ltd. Sponsored ADR (BWAY) have gained 7.1% over the past four weeks to close the last trading session at $11.49, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $15.05 indicates a potential upside of 31%.The average comprises four short-term price targets ranging from a low of $14.20 to a high of $16.00, with a standard deviation of $0.74. While the lowest es ...

Company Overview - Brainsway Ltd. shares (BWAY) experienced a 5.3% increase, closing at $11.49, with notable trading volume compared to typical sessions [1] - The company is expected to report quarterly earnings of $0.04 per share, unchanged from the previous year, with revenues projected at $12.39 million, reflecting a 23.8% increase year-over-year [3] Clinical Trial Results - The recent rise in BWAY shares is linked to positive market sentiment following successful clinical trial results for BrainsWay's accelerated Deep TMS therapy for Major Depressive Disorder (MDD) [2] - The multicenter, randomized study showed statistically significant improvements in depression symptoms, a favorable safety profile, and rapid onset of effect, positioning BrainsWay's technology as a leading non-invasive treatment option for MDD [2] Earnings Estimates and Market Sentiment - The consensus EPS estimate for Brainsway has been revised 10% higher in the last 30 days, indicating a positive trend that typically correlates with price appreciation [4] - The stock currently holds a Zacks Rank of 3 (Hold), suggesting a neutral outlook in the market [5] Industry Comparison - Brainsway operates within the Zacks Medical - Products industry, where Boston Scientific (BSX) also competes, having closed 1.1% higher at $102.36, but with a -3.1% return over the past month [5] - Boston Scientific's consensus EPS estimate has increased by 0.1% to $0.72, representing a 16.1% change compared to the previous year [6]

Core Viewpoint - BrainsWay Ltd. announced preliminary results from a multicenter, randomized controlled trial indicating that the accelerated Deep TMS protocol for treating major depressive disorder is comparable in efficacy to the standard protocol while requiring fewer clinic visits [1][2]. Group 1: Study Overview - The trial involved 104 adult patients diagnosed with depression across eight sites, making it the largest randomized, controlled, blinded, multicenter trial of an accelerated Deep TMS protocol [2]. - Patients were divided into two groups: one receiving standard Deep TMS treatment and the other receiving the accelerated protocol [2]. Group 2: Treatment Protocol - The accelerated group underwent five sessions per day over six treatment days, followed by eight sessions over the next four weeks, significantly reducing the treatment burden [3]. - The primary endpoint was the change in depressive symptoms measured by the HDRS-21 scale, with secondary endpoints including response and remission rates [3]. Group 3: Key Findings - The accelerated Deep TMS group showed comparable efficacy with HDRS depression scores reduced by 18.9 points, while the standard group saw a reduction of 19.9 points [7]. - Response and remission rates were 87.8% and 78.0% for the accelerated group, compared to 87.5% and 87.5% for the standard group [7]. - Sessions for the accelerated protocol lasted less than 10 minutes, compared to 20 minutes for standard sessions [7]. - The median time to remission was 21 days for the accelerated group versus 28 days for the standard group [7]. - The accelerated protocol was well-tolerated with no serious adverse events reported, and side effects were mild [7]. Group 4: Company Commitment - BrainsWay emphasizes that innovation in mental health care involves not only new technology but also improving care delivery methods [5]. - The company is dedicated to expanding access to Deep TMS and advancing the field through scientific research [5]. - The accelerated protocol is investigational and not yet FDA-cleared, with preliminary results subject to further analysis and peer review [5]. Group 5: Company Background - BrainsWay is a leader in noninvasive neurostimulation treatments for mental health disorders, with a proprietary Deep TMS platform technology [8]. - The company has obtained three FDA-cleared indications for major depressive disorder, obsessive-compulsive disorder, and smoking addiction [8]. - Founded in 2003, BrainsWay operates in the United States and Israel, focusing on increasing global awareness and access to Deep TMS [8].

Core Insights - BrainsWay Ltd. is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, showcasing its Deep TMS technology at the Clinical TMS Society's 2025 Annual Meeting [1][4] - The company will present preliminary results from a multicenter randomized non-inferiority trial comparing its standard Deep TMS protocol to a novel accelerated protocol [2] - BrainsWay is the first and only TMS company to obtain three FDA-cleared indications, including major depressive disorder, obsessive-compulsive disorder, and smoking addiction [4] Company Overview - BrainsWay was founded in 2003 and operates in the United States and Israel, focusing on improving health through its proprietary Deep TMS platform technology [4] - The company is dedicated to advancing neuroscience and increasing global awareness and access to Deep TMS treatments [4] Clinical Research Highlights - The latest Deep TMS research will be featured in poster presentations at the conference, emphasizing the technology's advantages over first-generation TMS systems [3] - A Phase IV Registry Study demonstrated that 49% of patients successfully quit smoking after 15 treatment sessions using the Deep TMS H4 Coil [5] - A post-marketing surveillance study involving over 1,200 adolescent patients showed the efficacy and safety of Deep TMS for adolescent depression [5]

Brainsway Ltd. Sponsored ADR (BWAY) closed the last trading session at $10.46, gaining 20.1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $15.05 indicates a 43.9% upside potential.The mean estimate comprises four short-term price targets with a standard deviation of $0.74. While the lowest estimate of $14.20 indicates a 35.8% increase from the current price level, the most optim ...

Core Insights - BrainsWay has entered into a strategic equity financing agreement with Stella MSO, LLC to enhance access to mental health care and raise awareness of innovative treatments [1][2] - The investment in Stella is part of a broader strategy to make minority-stake investments in high-performing mental health providers across the U.S. [2] - BrainsWay will invest $5 million in Stella, acquiring a minority position in the company through preferred, annually compounding securities [4] Company Overview - BrainsWay is a leader in noninvasive neurostimulation treatments for mental health disorders, utilizing its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) technology [5] - The company has received FDA clearance for three indications: major depressive disorder, obsessive-compulsive disorder, and smoking addiction [5] - BrainsWay aims to increase global awareness and access to Deep TMS through ongoing clinical trials and scientific advancements [5] Stella Overview - Stella is an interventional psychiatry practice focused on effective mental health protocols for conditions such as severe trauma, stress, anxiety, and depression [6] - The organization has a strong reputation for clinical excellence and operational strength, having treated over 30,000 patients across more than 20 clinics [1][6] - Stella's partnership with BrainsWay is expected to accelerate its growth and enhance patient care [3][5]

Core Insights - BrainsWay Ltd. has entered into a strategic equity financing agreement with Stella MSO, LLC to enhance access to innovative mental health treatments [1][2] - The investment of $5 million will provide BrainsWay with a minority position in Stella, aimed at supporting the interventional psychiatry space [4][2] - This partnership is expected to accelerate growth and improve patient care through Stella's established network of mental health clinics [3][5] Company Overview - BrainsWay is a leader in noninvasive neurostimulation treatments for mental health disorders, utilizing its proprietary Deep TMS™ technology [5] - The company has received FDA clearance for three indications: major depressive disorder, obsessive-compulsive disorder, and smoking addiction [5] - BrainsWay is focused on advancing neuroscience and increasing global awareness of its treatment options [5] Stella Overview - Stella is an interventional psychiatry practice that addresses severe trauma, stress, anxiety, and depression through a multidisciplinary approach [6] - The organization has a strong reputation for clinical excellence and operational strength, having treated over 30,000 patients [1][6] - Stella aims to expand access to transformative mental health care through its network of clinics [3][5]

Brainsway Ltd. Sponsored ADR (BWAY) could be a solid choice for investors given the company's remarkably improving earnings outlook. While the stock has been a strong performer lately, this trend might continue since analysts are still raising their earnings estimates for the company.The rising trend in estimate revisions, which is a result of growing analyst optimism on the earnings prospects of this company, should get reflected in its stock price. After all, empirical research shows a strong correlation ...

Core Viewpoint - Brainsway Ltd. (BWAY) has shown a significant price increase of 35.5% over the past four weeks, with analysts projecting further upside potential based on a mean price target of $15.05, indicating a 41.3% increase from the current price of $10.65 [1] Price Targets and Analyst Estimates - The mean price target consists of four short-term estimates with a standard deviation of $0.74, where the lowest estimate is $14.20 (33.3% increase) and the highest is $16 (50.2% increase) [2] - A low standard deviation among price targets suggests a strong consensus among analysts regarding the stock's price direction and magnitude [9] Earnings Estimates and Market Sentiment - Analysts have shown increasing optimism about BWAY's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which historically correlates with stock price movements [11] - The Zacks Consensus Estimate for the current year has risen by 11.1% over the past month, with two estimates increasing and one decreasing [12] - BWAY holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, suggesting strong potential for near-term upside [13]